QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration

Summary

This is a phase 2, randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Timeline

Start

2022-06-29

Primary completion

2024-06-24

Completion

2024-06-24

Drugs

Indications